Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 4/20 | 0.43 |
| ▸ | FEN1 | P39748 | 3/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.41 |
| ▸ | CDK8 | P49336 | 7/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.39 |
| ▸ | CDK7 | P50613 | 2/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | CCNC | P24863 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | CCNH | P51946 | 1/20 | 0.39 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.39 |
| ▸ | PLK4 | O00444 | 1/20 | 0.39 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31068317 | 1.00 | ALOX5AP (0.43) | ALOX5APFEN1PARP10PARP11DDB1 | |
| SCHEMBL31068205 | 0.82 | DRD2 (0.43) | ALOX5APFEN1PARP10PARP11DDB1 | |
| SCHEMBL31068306 | 0.81 | CREBBP (0.45) | DDB1CRBN | |
| SCHEMBL31068269 | 0.77 | FABP4 (0.49) | DDB1CRBNCLK2CDK5CLK4 | |
| SCHEMBL29348682 | 0.77 | FABP4 (0.49) | DDB1CRBNCLK2CDK5CLK4 | |
| SCHEMBL31068241 | 0.77 | DDB1 (0.56) | DDB1CRBN | |
| SCHEMBL29348691 | 0.77 | FEN1 (0.41) | ALOX5APFEN1DDB1CRBN | |
| SCHEMBL29348366 | 0.76 | DDB1 (0.49) | DDB1CRBN | |
| SCHEMBL31068152 | 0.75 | ALOX5AP (0.46) | ALOX5APFEN1 | |
| SCHEMBL31068174 | 0.75 | PIK3CD (0.42) | DDB1CRBNMKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4648853-A1 | TARGETED DEGRADATION OF VAV1 | Monte Rosa Therapeutics AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-12257247-B2 | Targeted degradation of VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-03-25 | — | — | US | disclosed |
| US-20240285604-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-29 | — | — | US | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240285604-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | ALOX5AP 3723/4885FEN1 2128/4885PARP10 3464/4885 |
| US-12257247-B2 | Targeted degradation of VAV1 | VAV1, KRAS, CBL | ALOX5AP 3723/4885FEN1 2128/4885PARP10 3464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.